The Ole Miss Toxicology Came Back. Whippets and Cough Syrup. Watch How Much Coverage This Gets.
The Ole Miss toxicology came back. Aidan Hamilton died from nitrous oxide asphyxiation. Robert Strang died from polysubstance including cough syrup. The headlines are still calling them kratom pill deaths. Three weeks ago we said this is exactly what would happen. Here's the proof.
No Imminent Hazard Documented. No Public Comment. No Judicial Review. The DEA's 7-OH Ban Moves Forward While NIH Develops a Prescription Kratom Drug.
The DEA's 7-OH ban cannot take effect before November 13. No imminent hazard has been publicly documented. No public comment period applies to the actual order. The action is not subject to judicial review. Meanwhile NIH is developing a prescription kratom drug within the same department that recommended scheduling. Here is the complete documented timeline.
No Toxicology. No Confirmed Cause. How Two Ole Miss Deaths Were Weaponized for the Kratom Prohibition Campaign.
Two Ole Miss students died September 21. The products found were not natural kratom but synthetic scheduled compounds. Toxicology is still pending. A synthetic opioid ten times more potent than fentanyl was circulating on campus simultaneously. The national press ran kratom overdose headlines anyway. This is the story behind the story.
Cat's Claw Is the New Kratom. The Same Campaign Just Found a New Target
Something is happening to Cat's Claw right now that should look familiar to anyone paying attention to kratom. Counterfeit products containing newly-scheduled synthetic compounds are generating alarm about an entirely innocent botanical. The science, the pharmacology, and the supply chain record tell a different story.
The Government Filed to Develop a Prescription Kratom Replacement. 30 Days Later It Moved to Schedule the Plant.
On June 1, 2026, the National Institutes of Health announced that its Investigational New Drug application for purified mitragynine had taken effect with the FDA. Thirty days later, the DEA moved to schedule 7-hydroxymitragynine and three synthetic derivatives as Schedule I controlled substances. Both actions trace back to the same federal department. This is not a coincidence. It is a sequence.
Does 7-OH Actually Meet the Legal Standard for Emergency Scheduling?
The DEA doesn't just have to believe 7-OH is dangerous — it has to meet a specific legal standard to schedule it this way, and the record it built doesn't clear that bar on its own terms. A two-year Schedule I placement, no judicial review, and a "good cause" exception invoked against a product sold openly for years. This piece reads the DEA's own notice, sentence by sentence, and shows where the case falls apart.
If 7-OH Is "Synthetic," Where's the Patent? The Contradiction at the Heart of the Ban
Regulators keep calling 7-OH a "synthetic opioid." But you can't patent a natural compound, and no one holds a patent on 7-OH — because it's a naturally occurring plant alkaloid. Meanwhile, pharmaceutical companies are patenting genuinely synthetic versions to sell. It can't be synthetic enough to ban and natural enough to be unpatentable. The contradiction, exposed.
The American Kratom Association Is Calling 7-OH a "Synthetic Opioid." It Isn't. And They Know It.
When the DEA moved to schedule 7-OH, the American Kratom Association cheered — and repeated the claim that 7-OH is a dangerous synthetic opioid. It isn't. It's a naturally occurring kratom alkaloid, present in every batch of leaf AKA's own members sell. Here's why their "protect the leaf, sacrifice 7-OH" strategy is scientifically wrong, strategically self-defeating, and who it actually protects.
DEA Files Notice of Intent to Schedule 7-Hydroxymitragynine: What It Actually Means — and Who Gets Hurt
DEA filed a notice of intent July 1, 2026 to temporarily schedule 7-hydroxymitragynine. The comment period closes July 31. Here's what was actually filed, what the threshold means, and who gets hurt.